Impact of Effective T1/2 and Cumulated Blood Activity Concentration on L2–L4 Imaging-Based Marrow Dose
| Whole-body T1/2 (h) | Blood T1/2, 1 compartment (h) | Blood cumulated activity (GBq-s/mL) | Change in marrow dose (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Group | Radionuclide | Mean | Range | Mean | Range | Mean | Range | Mean | Range |
| 1 (n = 5) | 111In-B9E9 pretarget | 33 | 26–40 | 16 | 10–22 | 0.27 | 0.13–0.40 | 3 | 1–7 |
| 2 (n = 8) | 111In-ibritumomab tiuxetan | 55 | 49–61 | 31 | 30–35 | 4.3 | 2.0–6.9 | 17 | 9–24 |
| 3 (n = 4) | 131I-HuCC49ΔCh2 | 38 | 32–42 | 20 | 19–25 | 8.9 | 6.7–10.8 | 24 | 15–28 |
| 4 (n = 9) | 111In-CC49 | 61 | 56–64 | 54 | 38–70 | 3.3 | 1.5–5.1 | 15 | 6–26 |